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An observational study of alemtuzumab
following fingolimod for multiple sclerosis
ABSTRACT
Objective: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced
significant and unexpected disease activity within the first 12 months after switching from fingo-
limod to alemtuzumab.
Methods: Patients with relapsing MS treated sequentially with fingolimod then alemtuzumab who
experienced significant subsequent disease activity were identified by personal communication
with 6 different European neuroscience centers.
Results: Nine patients were identified. Median disease duration to alemtuzumab treatment was
94 (39–215) months and follow-up from time of first alemtuzumab cycle 20 (14–21) months.
Following first alemtuzumab infusion cycle, 8 patients were identified by at least 1 clinical relapse
and radiologic disease activity and 1 by significant radiologic disease activity alone.
Conclusions: We acknowledge the potential for ascertainment bias; however, these cases may
illustrate an important cause of reduced efficacy of alemtuzumab in a vulnerable group of patients
with MSmost in need of disease control. We suggest that significant and unexpected subsequent
disease activity after alemtuzumab induction results from prolonged sequestration of autoreac-
tive lymphocytes following fingolimod withdrawal, allowing these cells to be concealed from
the usual biological effect of alemtuzumab. Subsequent lymphocyte egress then provokes dis-
ease reactivation. Further animal studies and clinical trials are required to confirm these phenom-
ena and in the meantime careful consideration should be given to mode of action of individual
therapies and sequential treatment effects in MS when designing personalized treatment
regimens. Neurol Neuroimmunol Neuroinflamm 2017;4:e320; doi: 10.1212/NXI.0000000000000320
GLOSSARY
ARR 5 annualized relapse rate; DMT 5 disease-modifying treatment; IFN 5 interferon; MS 5 multiple sclerosis; Treg 5
regulatory CD41 T cell.
The pathophysiology of multiple sclerosis (MS) involves a complex interplay of immunologic
factors, including a pivotal role for T and B lymphocytes. As a result, current disease-
modifying treatments (DMTs) are targeted at immune cell trafficking, lymphocyte function,
and lymphodepletion.1 With a growing range of interventions now available for relapsing
disease, it has become of increasing importance to understand their place and timing in indi-
vidualized therapy. In addition, the immediate and long-term consequences of sequential drug
use and the optimum order in which they should be used is unclear but may significantly affect
efficacy, adverse events, and longer-term immunocompetence. While awaiting clinical studies to
address these issues, observations from clinical practice will be of value in guiding current
protocols, generating hypotheses, and informing trial design.
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We report a case series of 9 patients from 6
European neuroscience centers who switched
to alemtuzumab following incomplete sup-
pression of inflammatory disease activity by
fingolimod. Despite the established efficacy
of alemtuzumab, which reduces relapse
frequency by up to 74% against an active com-
parator (interferon [IFN]–b-1a), and annual-
ized relapse rates (ARR) from 2.1 to 0.2 in
open-label studies,1 all patients experienced
a lack of response to alemtuzumab with signif-
icant new disease activity. We hypothesize that
this occurs as a result of prolonged lymph node
sequestration of circulating lymphocytes fol-
lowing fingolimod withdrawal, which in turn
limits the efficacy of alemtuzumab. In human-
ized mice, CD52-positive lymphocyte lysis is
more profound in the peripheral circulation
compared to the degree of depletion in lym-
phoid organs2 and suggests that in some pa-
tients lymphocytes may remain concealed
from the usual therapeutic effects of alemtu-
zumab. This may have important implications
for sequential drug selection and washout pe-
riods in a subset of patients who switch from
fingolimod or drugs with similar biological
mechanisms.
METHODS Patients with relapsing MS treated sequentially
with fingolimod followed by alemtuzumab were identified as
having significant and unexpected subsequent disease activity
by personal communication with 6 European neuroscience
centers. History was obtained by clinical note review and
radiologic outcomes analyzed.
RESULTS Table 1 summarizes clinical information
for each patient. All values are median times with
ranges in parentheses. Age at disease onset was 22
(8–32) years and disease duration to alemtuzumab
treatment 94 (39–215) months. Follow-up from
first alemtuzumab cycle was 20 (14–21) months.
Time on fingolimod was 13 months (5–33). All
patients had received additional DMTs prior to
fingolimod: 7 received IFN-b and 2 natalizumab as
first-line therapy. Of patients commenced on IFN, 6
escalated to natalizumab, with 1 patient proceeding
directly to fingolimod (table 2). Clinical disease or
radiologic disease activity were principal reasons for
switching from IFN-b and glatiramer acetate but in 8
patients who transitioned from natalizumab to
fingolimod only 1 switched as a result of clinical
disease activity.
Median fingolimod washout period was 6 (4–
10) weeks prior to first alemtuzumab cycle. At first
treatment, 5 patients had lymphocyte counts below
normal range (median 0.64 3 109/L, range 0.24–
1.76 3 109) and in 4 patients lymphocytes recon-
stituted more rapidly than expected (median 3
months). Following initial infusion, 8/9 patients
experienced at least 1 clinical relapse in the first
12 months (ARR 1.6) with all patients having
radiologic evidence for new disease activity on
MRI in the form of new T2 lesions or gadolinium
(Gd)–enhancing lesions (table 1 and figure).
Median time to relapse following alemtuzumab
induction was 4.5 months.
Despite the presence of disease activity in the first
12 months, all patients went on to receive the second
planned infusion of alemtuzumab and further follow-
up is currently available for a mean of 6 months from
second treatment cycle. During this period, 8 patients
Table 1 Summary of clinical cases
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9
Sex F F M M F F M M F
Age at onset, y 8 22 25 24 17 16 20 32 28
DMT sequence Inf; Nat; Fing;
Alem
Inf; Fing;
Alem
Nat; Fing;
Alem
Inf; Nat; Fing;
Alem
Inf; Nat; Fing;
Alem
Inf; Gla; Nat; Fing;
Alem
Inf; Nat; Fing;
Alem
Nat; Fing;
Alem
Inf; Gla; Nat; Fing;
Alem
Duration of Fing, mo 17 20 21 5 6 33 13 5 10
Washout: Fing-Alem, wk 4 8 8 6 10 7 5 2.5 4
Pretreatment L count
(3109/L)
1.35 1.40 0.42 0.64 1.76 1.55 0.24 0.50 0.60
L reconstitution N Y N N N Y N Y Y
Relapses 3 2 2 2 1 1 2 1 0
T2 .10 9 2 .10 0 .10 .10 1 1
Gd1 6 5 0 7 2 13 4 5 1
Abbreviations: Alem 5 alemtuzumab; DMT 5 disease-modifying treatment; Fing 5 fingolimod; Gd1 5 number of gadolinium-enhancing lesions; Gla 5
glatiramer acetate; Inf 5 interferon; L 5 lymphocyte; Nat 5 natalizumab; T2 5 number of new T2 lesions.
Lymphocyte reconstitution, relapses, T2, and Gd1 are all in the 12 months following first alemtuzumab cycle.
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Table 2 Disease-modifying treatment summary
Interferon-b Glatiramer acetate Natalizumab Fingolimod
Case 1
Duration of treatment, mo 20 — 29 17
Reason for stopping Clinical and radiologic
disease activity
— Clinical disease activity, JC
virus concerns
Clinical and radiologic
disease activity
New/Gd1 lesions Yes — No Yes
Relapses 2 — 2 1
Case 2
Duration of treatment 41 — — 20
Reason for stopping Clinical disease activity — — Clinical disease activity
New/Gd1 lesions No — — Yes
Relapses 1 — — 1
Case 3
Duration of treatment — — 30 21
Reason for stopping — — JC virus concerns Clinical and radiologic
disease activity
New/Gd1 lesions — — No Yes
Relapses — — 1 2
Case 4
Duration of treatment 33 — 34 5
Reason for stopping Clinical and radiologic
disease activity
— JC virus concerns Radiologic disease
activity, fatigue
New/Gd1 lesions Yes — No Yes
Relapses 1 — 0 0
Case 5
Duration of treatment 66 — 24 mo, stopped for 9 mo then
restarted due to relapse;
6
continued on for 36 mo and
stopped because of pregnancy
Reason for stopping Side effects — Pregnancy Radiologic disease
activity
New/Gd1 lesions Yes — Yes during stop period; apart
from that no new lesions
Yes
Relapses 0 — 0 0
Case 6
Duration of treatment 1 36 One infusion only 33
Reason for stopping Side effects Clinical disease activity Side effects (allergic reaction) Clinical and radiologic
disease activity
New/Gd1 lesions NA Yes NA Yes
Relapses 0 4 NA 4
Case 7
Duration of treatment 18 — 13 13
Reason for stopping Clinical and radiologic
disease activity
— JC virus concerns Clinical and radiologic
disease activity
New/Gd1 lesions Yes — No Yes
Relapses 3 — 0 2
Case 8
Duration of treatment — — 64 5
Reason for stopping — — JC virus concerns Clinical disease activity
New/Gd1 lesions — — No Yes
Continued
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have been relapse-free (combined ARR 0.3). Seven
patients have had further imaging: 4 patients were
radiologically stable and 3 developed new T2 lesions,
1 of whom had a single new Gd-enhancing lesion.
Two patients have not yet undergone further interval
imaging.
DISCUSSION Fingolimod is an oral DMT causing
internalization of S1P type 1 receptors and inhibition
of lymphocyte trafficking from secondary lymphoid
organs into the peripheral circulation. This results
in a reduction of the number of lymphocytes available
to cross the blood–brain barrier into the CNS, which
is thought to be responsible for reducing disease
activity.3
Alemtuzumab is a humanized monoclonal anti-
body targeted against the cell surface protein CD52.
Treatment results in a rapid and profound reduction
in peripheral lymphocytes as a result of antibody-
dependent cell-mediated cytotoxicity, complement-
dependent cytolysis, and induction of apoptosis.1
Repopulation occurs through proliferation of mature
lymphocytes that escape deletion or by thymic repo-
pulation from CD52-negative hematopoietic precur-
sors.4 A relative increase in regulatory CD41 T cells
(Tregs) is observed following treatment and repopu-
lation5 together with an increased representation of
memory T lymphocytes.6 This pattern of subsequent
reconstitution of the immune system is thought to be
beneficial for MS.
Fingolimod has a pharmacologic half-life of 6–9
days7 and lymphocytes would be expected to normal-
ize 2–4 weeks after discontinuation.3 However, there
are case reports of prolonged lymphopenia following
Table 2 Continued
Interferon-b Glatiramer acetate Natalizumab Fingolimod
Relapses — — 0 1
Case 9
Duration of treatment 5 76 81 10
Reason for stopping Side effects Clinical disease activity JC virus concerns Radiologic disease
activity
New/Gd lesions NA Yes No Yes
Relapses 0 2 0 0
Abbreviation: Gd1 5 gadolinium enhancing lesions.
Figure Axial T1 plus contrast images (time post alemtuzumab)
(A) Case 1 (8 months). (B) Case 2 (10 months). (C) Case 4 (8 months). (D) Case 8 (7 months). (E) Case 9 (6 months). White
arrows 5 new gadolinium-enhancing lesions.
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prolonged drug exposure, up to 37 months after dis-
continuation.8 Following discontinuation, there is
also a risk of rebound disease activity 2–4 months
from the time of withdrawal.3 In animal models,
rebound is preceded by a burst of S1P1 overexpres-
sion in trapped lymphocytes, which also correlates
with subsequent massive lymphocyte egress and
CNS infiltration. In addition, Treg functionality is
impaired following cessation of fingolimod, which
may also contribute to rebound activity.3 It has there-
fore been suggested that patients continue on an alter-
native DMT after fingolimod discontinuation,
preferably until peripheral lymphocyte counts have
normalized. There is currently no consensus as to
which subsequent therapeutic agent is optimal.
Following alemtuzumab, there is a significant
reduction in relapse frequency, with phase III trials
demonstrating 60%–74% of patients at 24 months
having freedom from clinical disease, defined as the
absence both of relapses and sustained accumulation
of disability. In addition, only 7%–9% of patients
had gadolinium-enhancing lesions at 24 months on
annually performed MRI.1
In our own published cohort9 of 100 patients trea-
ted with alemtuzumab, only 4 patients experienced.1
relapse in the 12 months after initial infusion. In con-
trast, all 9 patients reported here experienced signifi-
cant and unexpected disease activity. We consider the
radiologic findings of these cases particularly striking,
especially given the relatively short follow-up time.
We hypothesize that the significant and unex-
pected disease activity in these cases is caused by se-
questrated lymphocytes, which remain concealed
from the usual therapeutic effects of alemtuzumab,
which has a relatively short half-life of between 7
and 21 days.10 Following this period, surviving
CD52-positive lymphocytes then egress from lymph
nodes, initiating the observed inflammatory disease
activity. Variability in lymphocyte reconstitution
may also contribute to these effects: in case 2, it took
only 2 months for the peripheral lymphocyte count to
return to normal range following the first cycle of
alemtuzumab and 1 month after the second cycle.
This is considerably faster than the reported mean
of 7.1 months for B cells and 20 and 35 months
for CD81 and CD41 T cells, respectively.1
Other factors that may influence disease activity
include S1P1 overexpression and subsequent lympho-
cyte egress contributing to accelerated repopulation3
and modification of the circulating immune repertoire
by fingolimod altering the expected deletion pattern
following alemtuzumab. In support of this, 5 patients
remained lymphopenic at the start of treatment. In the
4 who had normal lymphocyte counts, it could
be speculated that an altered repopulating immune
repertoire and impaired Treg functionality may be
contributing to the observed disease activity. Alterna-
tively, it may be that for some patients, pathogenic
lymphocytes may continue to be released from the
lymphoid system over a more prolonged period. While
on fingolimod, the mean ARR was 1, increasing to 1.6
in the 12 months following alemtuzumab then reduc-
ing to 0.3 following the second dose to date, lending
some support to the hypothesis that, after a period,
sequestrated lymphocytes eventually become available
for depletion by alemtuzumab.
Across the 6 centers, a total of 174 patients have
been treated with alemtuzumab. Of these, 36 received
fingolimod prior to administration of alemtuzumab.
Therefore, these 9 patients with unexpected and sig-
nificant disease activity following alemtuzumab repre-
sent 25% of the fingolimod-alemtuzumab cohort.
Detailed outcome data are not currently available
on all 174 patients treated with alemtuzumab but
would clearly represent a valuable resource for more
detailed investigation. Therefore, although we recog-
nize the potential for selection bias in this case series,
the degree of disease activity observed in these cases
spontaneously and independently caught the atten-
tion of clinicians in different centers and may repre-
sent an important cause of lack of therapeutic
efficacy in a group of patients most at need of disease
control. Further studies including detailed immuno-
phenotyping are required to confirm these phenom-
ena and may have relevance in understanding causes
of disease reactivation in general. In addition, future
trials addressing longer-term outcomes of induction
and escalation paradigms need to be designed in order
to guide clinicians on strategies for treatment
switches. In particular, careful consideration needs
to be given to mode of action of individual therapies
and sequential treatment effects.
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